Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × CNS × Clear all

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Phase 1/2 Recruiting

3 enrolled

BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT05388435 2025-05-04

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Phase 1/2 Terminated

15 enrolled

BreastCNSThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Triple Negative Breast Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 2 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer